RESULTS Among the 1851 patients, the mean SRI was 85.4% AE 23.4%, ranging from 4% to 100%. Complete revascularization (SRI¼100%) was achieved in 64.3% of patients, SRI¼ 50-99% in 472 patients (25.5%), and SRI <50% in 189 patients (10.2%). The 2-year rates of mortality (0.4%, 1.9%, and 2.7%, p¼0.001) and MACE (6.0%, 11.4%, and 10.1%, p<0.001) were higher in patients with lower SRI. By ROC analysis, an SRI cut-off of 85% showed the best prognostic accuracy for 2-year mortality. A SRI of !85% had similar low allcause death and cardiac death rates when compared to complete (SRI¼100%) revascularization (Figure) . By multivariable analysis, SRI was a strong predictor of 2-year mortality (HR: 4.20, 95% CI: 1.46-12.08, p¼0.008) and 2-year MACE (HR: 1.59, 95% CI: 1.14-2.23, p¼0.007).
BACKGROUND Recurrent chest pain after successful percutaneous coronary intervention (PCI) is the main trigger of repeat assessment and resource utilization. PCI of bifurcated target lesions are often complex and bear a higher risk of adverse events and chest pain.
METHODS
To compare 2-year clinical outcome and patient-reported chest pain of patients with bifurcated vs. non-bifurcated lesions, we assessed data of the DUTCH PEERS randomized trial (clinicaltrials.gov NCT01331707), in which 1,811 all-comers were treated with zotarolimus-eluting Resolute Integrity (Medtronic) or everolimus-eluting Promus Element (Boston Scientific) stents. Among 465 patients with bifurcated lesions, we also compared the outcome of patients with true bifurcation lesions (i.e. lesions with side-branch involvement) vs. non-true bifurcation lesion. The primary endpoint target lesion failure (TLF) is a composite of cardiac death, target vessel myocardial infarction (MI), and target lesion revascularization.
RESULTS Clinical follow-up was available in 1,810 patients (99.9%). TLF was similar in patients with and without bifurcated lesions (8.2% vs. 6.9%, p¼0.37). Target vessel MI was more common in patients with bifurcated lesions, however, after multivariate analysis with use of a propensity score, this relation turned out to be not statistically significant (HR 1.40, p¼0.34) . There was no difference in TLF between patients treated for true vs. non-true bifurcation lesions (8.9% vs. 7.8%, p¼0.70). At 1 and 2-year followup, 88.0% and 88.1% of patients with bifurcated lesions and 87.7% and 87.8% of patients with non-bifurcated lesions were free from clinically relevant chest pain (p¼0.89 and 0.87, respectively). Between patients with true vs. non-true bifurcation lesions, no difference in patient-reported chest pain at 1 and 2-year follow-up was observed (86.5% vs. 88.5%, p¼0.54, and 90.2% vs. 86.7%, p¼0.30, respectively) .
CONCLUSIONS The rates of chest pain were low and similar in patients with bifurcated versus non-bifurcated target lesions, who showed favorable clinical outcomes at 1 and 2-year follow-up after treatment with contemporary flexible drug-eluting stents. BACKGROUND High-risk percutaneous coronary intervention (PCI) supported by percutaneous left ventricular assist devices offers a treatment option for patients with severe symptoms, complex and extensive coronary artery disease (CAD), and multiple comorbidities. The extrapolation from clinical trial to real-world practice has inherent uncertainties. We compared the characteristics, procedures, and outcomes of high-risk PCI supported by a microaxial pump (Impella 2.5) in a multicenter registry versus the randomized PRO-TECT II trial (NCT00562016).
METHODS The USpella registry is an observational multicenter voluntary registry of lmpella technology in 47 sites in the United States and 2 sites in Canada. A total of 637 patients undergoing highrisk PCI supported by Impella 2.5 between 6/2007 and 9/2013 were included in this analysis. Of them, 339 patients would have met enrollment criteria for the PROTECT II trial. Baseline variables, procedural characteristics, and in-hospital outcomes of these registry patients were compared with 216 patients treated in the Impella arm of the PROTECT II trial. All events were centrally adjudicated by an independent clinical events committee.
RESULTS Compared to the clinical trial, registry patients were older (70AE11.5 vs. 67.5AE11.0 years), more likely to have chronic kidney disease (30% vs. 22.7%), prior myocardial infarction (69.3% vs. 56.5%), prior by-pass surgery (39.4% vs. 30.2%), and had similar prevalence of diabetes, peripheral vascular disease, and prior stroke. Registry patients had more extensive CAD (2.2 vs. 1.8 diseased vessels), and had a similar STS predicted risk of mortality (6.0AE6.0 vs. 5.8AE6.0, p¼0.64). Left ventricular ejection fraction was 23.4AE6.3% and 21.6AE7.7%, in the registry and clinical trial, respectively (p¼0.004). Use of rotational atherectomy was similar (16.4% vs. 14.8%, p¼0.63), but the number of passes per lesion was significantly lower in the registry (2.56AE2.20 vs. 3.47AE1.89, p¼0.003). At hospital discharge, registry patients experienced a 42% reduction in NYHA class III-IV symptoms. In-hospital mortality was numerically lower among registry patients (2.7% vs. 4.6, p¼0.27). Need for blood transfusions were similar in registry and clinical trial patients (9.1% vs. 12.5%, p¼0.21). There were no differences in the occurrence of other complications such as acute kidney failure, vascular injury or ventricular arrhythmias.
CONCLUSIONS USpella provides a real world and contemporary estimation of the type of procedures and outcomes of high-risk patients undergoing PCI supported by Impella 2.5. Despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial. BACKGROUND We sought to describe contemporary guidewire utilization for antegrade wire escalation during chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
We examined guidewire and microcatheter utilization during antegrade wire escalation attempts among 1097 CTO PCIs performed at 13 experienced US centers between May 2012 and April 2015 using the hybrid approach.
RESULTS Mean age was 65 AE 9.8 years, 83.2% of the patients were men and 33.3% had prior coronary bypass graft surgery. Technical and procedural success was 90.6% and 87.6%, respectively. Antegrade wire escalation was used in 780 procedures (71.1%), and was the final successful crossing strategy in 463 procedures (59.3%). A total of 1630 guidewires (2.4 AE 1.4 per procedure) were used for antegrade wire escalation. The most frequently used guidewires were the Pilot 200 (Abbott Vascular, 24.7%), Fielder XT (Asahi Intecc, 19.7%), and the Confianza Pro 12 (Asahi Intecc, 12.6%) (Figure 1) . The same guidewires were the ones that most commonly led to successful CTO crossing: Pilot 200 (35.2% of successful antegrade wire crossings), Fielder XT (20%) and Confianza Pro 12 (10.7%). A microcatheter or over-the-wire balloon was used in 73.8% of antegrade wire escalation cases, as follows: Corsair (Asahi-Intecc, 42.8%), Finecross (Terumo, 18.6%), overthe-wire balloon (14.2%), CrossBoss (Boston Scientific, 12.7%), and Venture (St Jude Medical, 3.3%).
CONCLUSIONS Our contemporary, multicenter CTO PCI registry demonstrates remarkable consistency in guidewire selection for antegrade wire escalation, with polymer-jacketed guidewires being used in most cases including most successfully crossed cases. Upfront use of the Pilot 200 guidewire might offer the best chance for successful guidewire crossing. Quebec Heart and Lung Institute, Quebec city, Quebec; 2 Laval University/Québec Heart And Lung Institute, Quebec City, Canada BACKGROUND The prevalence of native coronary CTO following coronary artery bypass grafts (CABG) is high. At 10 years following CABG, half patients will have at least one saphenous vein graft (SVG) occluded and/or many SVGs will be diseased. Long-term outcome post SVG PCI is poor, with high occlusion rate. If symptomatic, these patients may be considered for a native coronary CTO PCI rather than SVG PCI. We examined the feasibility and outcomes of CTO PCI using a patent or occluded SVG as a retrograde conduit to the native CTO vessel.
METHODS Our preferred wire to cross an occluded SVG is Pilot 200 (Abbott Vascular, US) followed by a microcatheter (MC) (usually Corsair, Asahi Intecc, Japan), whereas standard workhorse wire can be used in patent but diseased SVGs or arterial graft. MC tip injection is performed to assess if the wire tracked the vein structure in case of an occluded SVG. Clips and other surgical landmarks are used to track the occluded graft with the wire. Once the MC is at the distal CTO cap, standard techniques to open CTO are employed. We assessed the proportion of patients treated with such technique from SVGs. We specifically reviewed the J-CTO score, the prevalence of occluded vs. patent graft, the type of graft crossed (SVG or arterial graft), technical success and management of the graft after successful PCI of the native CTO.
RESULTS From 03.2009 to 04.2015 431 CTO PCI cases were performed by a single operator (SR) or a team of 2 operators (SR and CMN). Of these, 156 (36.2%) were done in post-CABG patients. In the post-CABG cohort, an antegrade approach was used in 68 (43.6%) and a retrograde in 88 (56.4%) of cases. In the retrograde approach, septal collateral channels (CCs) were used in 26 (29.5%), epicardial in 34 (38.6%) and SVGs in 28 (31.8%) of cases. Technical success of CTO revascularization in post-CABG patients (J-CTO score 2.51AE0.1) was 91%. In the sub-group treated from an SVG, mean J-CTO score was 3.04AE0.19. The CTO location was in the right coronary artery in 43%, left circumflex in 43%, left anterior descending in 7% and in the left main in 7%. When using an SVG, success was achieved in 27 cases (96.4%). A total of 15 SVGs (53.6%) were occluded before the retrograde attempt, and the oldest occlusion was 4-years old. Most common native coronary CTO recanalization
